Concord Drugs Ltd Fair Value
CONCORD · Healthcare · Current price ₹71.52
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹32 | 1% ROE fading to 12% over ~3 yrs, on ₹37 book |
| Relative P/E | ₹0 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹3 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Concord Drugs Ltd undervalued?
DocStoX estimates the fair value of Concord Drugs Ltd at ₹18 per share, versus the current market price of ₹72. That puts the stock about -74.2% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹32), Relative P/E (₹0), Graham floor (₹3). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹0 (bear) to ₹18 (base) to ₹32 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Concord Drugs Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.